Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 320

1.

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Intlekofer AM, Thompson CB.

J Leukoc Biol. 2013 Jul;94(1):25-39. doi: 10.1189/jlb.1212621. Epub 2013 Apr 26. Review.

2.

At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.

Callahan MK, Wolchok JD.

J Leukoc Biol. 2013 Jul;94(1):41-53. doi: 10.1189/jlb.1212631. Epub 2013 May 10. Review.

3.

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G.

Cancer Res. 2013 Jun 15;73(12):3591-603. doi: 10.1158/0008-5472.CAN-12-4100. Epub 2013 Apr 30.

4.

A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.

Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F.

Eur Urol. 2015 Aug;68(2):267-79. doi: 10.1016/j.eururo.2015.02.032. Epub 2015 Mar 29. Review.

PMID:
25824720
5.

Orchestrating immune check-point blockade for cancer immunotherapy in combinations.

Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, Sanmamed MF, Melero I.

Curr Opin Immunol. 2014 Apr;27:89-97. doi: 10.1016/j.coi.2014.01.002. Epub 2014 Jan 28. Review.

PMID:
24485523
6.

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.

Philips GK, Atkins M.

Int Immunol. 2015 Jan;27(1):39-46. doi: 10.1093/intimm/dxu095. Epub 2014 Oct 16. Review.

PMID:
25323844
7.

Checkpoint blocking antibodies in cancer immunotherapy.

Kyi C, Postow MA.

FEBS Lett. 2014 Jan 21;588(2):368-76. doi: 10.1016/j.febslet.2013.10.015. Epub 2013 Oct 23. Review.

8.

Immune checkpoint combinations from mouse to man.

Ai M, Curran MA.

Cancer Immunol Immunother. 2015 Jul;64(7):885-92. doi: 10.1007/s00262-014-1650-8. Epub 2015 Jan 3. Review.

PMID:
25555570
9.

Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data.

Swanson MS, Sinha UK.

Oral Oncol. 2015 Jan;51(1):12-5. doi: 10.1016/j.oraloncology.2014.10.010. Epub 2014 Oct 28. Review.

PMID:
25459157
10.

Immune Checkpoint Blockade in Cancer Therapy.

Postow MA, Callahan MK, Wolchok JD.

J Clin Oncol. 2015 Jun 10;33(17):1974-82. doi: 10.1200/JCO.2014.59.4358. Epub 2015 Jan 20. Review.

PMID:
25605845
11.

Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.

Allard B, Pommey S, Smyth MJ, Stagg J.

Clin Cancer Res. 2013 Oct 15;19(20):5626-35. doi: 10.1158/1078-0432.CCR-13-0545. Epub 2013 Aug 27.

12.

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

Weber J.

Semin Oncol. 2010 Oct;37(5):430-9. doi: 10.1053/j.seminoncol.2010.09.005. Review.

PMID:
21074057
13.

Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.

Duraiswamy J, Freeman GJ, Coukos G.

Cancer Res. 2013 Dec 1;73(23):6900-12. doi: 10.1158/0008-5472.CAN-13-1550. Epub 2013 Aug 23.

14.

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Ott PA, Hodi FS, Robert C.

Clin Cancer Res. 2013 Oct 1;19(19):5300-9. doi: 10.1158/1078-0432.CCR-13-0143. Review.

15.

Immune checkpoint blockade: a common denominator approach to cancer therapy.

Topalian SL, Drake CG, Pardoll DM.

Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. Epub 2015 Apr 6. Review.

16.

Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.

Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA.

Clin Cancer Res. 2010 Dec 15;16(24):6019-28. doi: 10.1158/1078-0432.CCR-10-1966. Epub 2010 Oct 5.

17.

Therapeutic use of anti-CTLA-4 antibodies.

Blank CU, Enk A.

Int Immunol. 2015 Jan;27(1):3-10. doi: 10.1093/intimm/dxu076. Epub 2014 Jul 18. Review.

PMID:
25038057
18.

[Immune-checkpoints: the new anti-cancer immunotherapies].

Ileana E, Champiat S, Soria JC.

Bull Cancer. 2013 Jun;100(6):601-10. doi: 10.1684/bdc.2013.1771. Review. French.

PMID:
23735730
19.

The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.

Blank CU.

Curr Opin Oncol. 2014 Mar;26(2):204-14. doi: 10.1097/CCO.0000000000000054. Review.

PMID:
24424272
20.

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.

Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM.

J Immunol. 2015 Feb 1;194(3):950-9. doi: 10.4049/jimmunol.1401686. Epub 2014 Dec 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk